APA (7th ed.) Citation

Sørensen, K. K., Yazdanfard, P. D. W., Zareini, B., Pedersen-Bjergaard, U., Kosjerina, V., Andersen, M. P., . . . Torp-Pedersen, C. (2025). Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes. Cardiovascular Diabetology, 24(1), 1. https://doi.org/10.1186/s12933-025-02915-1

Chicago Style (17th ed.) Citation

Sørensen, Kathrine Kold, et al. "Real-world Cardiovascular Effectiveness of Sustained Glucagon-like Peptide 1 GLP-1 Receptor Agonist Usage in Type 2 Diabetes." Cardiovascular Diabetology 24, no. 1 (2025): 1. https://doi.org/10.1186/s12933-025-02915-1.

MLA (9th ed.) Citation

Sørensen, Kathrine Kold, et al. "Real-world Cardiovascular Effectiveness of Sustained Glucagon-like Peptide 1 GLP-1 Receptor Agonist Usage in Type 2 Diabetes." Cardiovascular Diabetology, vol. 24, no. 1, 2025, p. 1, https://doi.org/10.1186/s12933-025-02915-1.